GGrantIndex
Sort

48,018 grants matching immunotherapy

Antibodies for BioDefense using Directed Evolution

$886,188
Diversa Corporation · U01 · FY2003 · AI

Immunotherapy for Type 1 Diabetes

$885,432
Francine R. Kaufman · Children'S Hospital Of Los Angeles · U01 · FY2007 · DK

Strategies for Prevention of Autoimmunity

$885,307
Stanford University · U19 · FY2003 · DK

Advancing treatment and understanding of immunotherapy in glioblastoma

$885,236
Nicholas A Butowski · University Of California, San Francisco · U19 · FY2021 · CA

Pediatric AIDS Clinical Trials Group

$885,194
University Of California San Diego · U01 · FY2003 · AI

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)

$885,149
Terry B Gernsheimer · University Of Washington · U01 · FY2019 · HL

Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy

$885,028
Marie Bleakley · Fred Hutchinson Cancer Center · P01 · FY2022 · CA

Blood-based Alzheimer's biomarker detection at the point of care

$885,006
Hadi Shafiee · Brigham And Women'S Hospital · R56 · FY2024 · AG

Immunotherapeutic Approaches for AIDS

$884,441
George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT

$884,360
Tulane University Of Louisiana · U01 · FY2001 · AI

Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy

$884,291
Marie Bleakley · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA

Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinoma

$884,176
Shumei Song · Coriell Institute For Medical Research · R01 · FY2025 · CA

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

$884,114
James L Abbruzzese · Duke University · UM1 · FY2016 · CA

UNIVERSITY OF P.R., PEDIATRIC AIDS CLINICAL TRIALS UNIT

$883,471
University Of Puerto Rico Med Sciences · U01 · FY2000 · AI

Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants

$883,231
Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI

Novel Hepatitis B Vaccine and Immunotherapy

$883,119
Mansun Law · Scripps Research Institute, The · R56 · FY2024 · AI

Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability

$882,648
Jana Portnow · Beckman Research Institute/City Of Hope · U19 · FY2024 · CA

Canine models for characterization, diagnosis, and treatment of human cancers using comparative canine-human transcriptomics

$882,530
Gregory Tawa · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR

Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors

$882,098
Jeffrey S Miller · University Of Minnesota · R35 · FY2024 · CA

Impact of Body Composition and Related Inflammatory and Immune States on Prognosis of Non-Muscle Invasive Bladder Cancer

$881,405
Marilyn L Kwan · Kaiser Foundation Research Institute · U01 · FY2023 · CA

SPORE in Pancreatic Cancer

$881,136
Donald J. Buchsbaum · University Of Alabama At Birmingham · P20 · FY2006 · CA

Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma

$880,830
Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2017 · DC

Biology and Therapy of Lymphopenia

$880,808
Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

In vivo hematopoietic stem cell engineering for HIV cure

$880,758
Hans-Peter Kiem · University Of Southern California · P01 · FY2025 · HL

Targeting PD-1 Pathway for Functional Cure of AIDS

$880,613
Rama Rao Amara · Emory University · R01 · FY2025 · AI